Comparative Pharmacology
Head-to-head clinical analysis: ARTHROTEC versus IBUPROFEN SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARTHROTEC versus IBUPROFEN SODIUM.
ARTHROTEC vs IBUPROFEN SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Arthrotec is a combination of diclofenac, a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, and misoprostol, a synthetic prostaglandin E1 analog that protects the gastric mucosa by increasing mucus and bicarbonate secretion, enhancing mucosal blood flow, and promoting epithelial repair.
Non-selective inhibitor of cyclooxygenase (COX-1 and COX-2), decreasing prostaglandin synthesis, resulting in anti-inflammatory, analgesic, and antipyretic effects.
One tablet (diclofenac 50 mg / misoprostol 200 mcg) orally twice daily with food.
200-400 mg orally every 4-6 hours, maximum 1200 mg/day; for OTC use, 200-400 mg every 6-8 hours as needed, maximum 1200 mg/day.
None Documented
None Documented
Diclofenac: ~2 hours (range 1-4 h); misoprostol: 20-40 minutes (acid metabolite 1.5 h). No accumulation with repeated dosing.
2.0-2.5 hours (terminal); no prolongation in mild hepatic impairment; increased in renal failure.
Renal: ~95% as metabolites (diclofenac: ~65% as glucuronide conjugates; misoprostol: ~80% as inactive metabolites). Biliary/fecal: <5%.
Renal: 90% as metabolites and conjugates, <1% unchanged; biliary/fecal: minor.
Category C
Category D/X
NSAID
NSAID